| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA596: Risankizumab for treating moderate to severe plaque psoriasis |
|
Medicine details |
|
| Medicine name | rizankizumab (Skyriz®) |
| Formulation | Subcutaneous injection |
| Reference number | 3148 |
| Indication | Treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy |
| Company | AbbVie Ltd |
| BNF chapter | Skin |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 19/05/25 |
| NICE guidance | TA596: Risankizumab for treating moderate to severe plaque psoriasis |